Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Sensei Biotherapeutics ( (SNSE) ).
Sensei Biotherapeutics has scheduled its 2026 annual shareholder meeting for June 10, 2026, where investors will vote on converting its Series B Non-Voting Convertible Preferred Stock into common shares, a move that would issue more than 20% new equity and trigger a change of control under Nasdaq rules. Ahead of the vote, the company released unaudited pro forma financials for the quarter ended March 31, 2026, reflecting the planned conversion tied to its February 17, 2026 acquisition of Faeth Therapeutics and a concurrent $200 million PIPE, while warning that the illustrative figures rely on preliminary assumptions and may differ from its actual post-conversion financial condition.
On February 17, 2026, Sensei acquired Faeth Therapeutics and issued 10,497.098 shares of Series B preferred stock to Faeth shareholders, equivalent to 10,497,098 common shares on an as-converted basis. At the same time it entered a securities purchase agreement with new and returning investors for an additional 14,440.395 Series B preferred shares, or 14,440,395 common shares on an as-converted basis, with all Series B preferred set to automatically convert into 1,000 common shares each upon shareholder approval, significantly reshaping the company’s capital structure and ownership profile.
The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.
Spark’s Take on SNSE Stock
According to Spark, TipRanks’ AI Analyst, SNSE is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity in TTM), which elevates financing and dilution risk. Technicals are also negative with the stock trading below key moving averages and bearish MACD, partially offset by oversold RSI/Stoch. Valuation remains challenged due to negative earnings and no dividend yield provided.
To see Spark’s full report on SNSE stock, click here.
More about Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. is a biotechnology company focused on developing therapeutic products, operating in a highly capital-intensive life sciences sector and listed on Nasdaq. Its shareholder base includes institutional and PIPE investors who have recently participated in preferred equity financing, positioning the company for expanded operations and post-merger integration.
Average Trading Volume: 78,047
Technical Sentiment Signal: Hold
Current Market Cap: $23.58M
For an in-depth examination of SNSE stock, go to TipRanks’ Overview page.